204 related articles for article (PubMed ID: 31422713)
1. Effects of vortioxetine on functional capacity across different levels of functional impairment in patients with major depressive disorder: a University of California, San Diego Performance-based Skills Assessment (UPSA) analysis.
Jacobson W; Zhong W; Nomikos GG; Christensen MC; Kurre Olsen C; Harvey PD
Curr Med Res Opin; 2020 Jan; 36(1):117-124. PubMed ID: 31422713
[No Abstract] [Full Text] [Related]
2. Vortioxetine improves symptomatic and functional outcomes in major depressive disorder: A novel dual outcome measure in depressive disorders.
Christensen MC; Loft H; McIntyre RS
J Affect Disord; 2018 Feb; 227():787-794. PubMed ID: 29689693
[TBL] [Abstract][Full Text] [Related]
3. Cost per successfully treated patient for vortioxetine versus duloxetine in adults with major depressive disorder: an analysis of the complete symptoms of depression and functional outcome.
Christensen MC; Munro V
Curr Med Res Opin; 2018 Apr; 34(4):593-600. PubMed ID: 29235884
[TBL] [Abstract][Full Text] [Related]
4. Validation of the University of California San Diego Performance-based Skills Assessment (UPSA) in major depressive disorder: Replication and extension of initial findings.
Christensen MC; Sluth LB; McIntyre RS
J Affect Disord; 2019 Feb; 245():508-516. PubMed ID: 30439678
[TBL] [Abstract][Full Text] [Related]
5. A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder.
Mahableshwarkar AR; Zajecka J; Jacobson W; Chen Y; Keefe RS
Neuropsychopharmacology; 2015 Jul; 40(8):2025-37. PubMed ID: 25687662
[TBL] [Abstract][Full Text] [Related]
6. A Subgroup Analysis of the Impact of Vortioxetine on Functional Capacity, as Measured by UPSA, in Patients with Major Depressive Disorder and Subjective Cognitive Dysfunction.
Keefe RSE; Nomikos G; Zhong W; Christensen MC; Jacobson W
Int J Neuropsychopharmacol; 2018 May; 21(5):442-447. PubMed ID: 29546401
[TBL] [Abstract][Full Text] [Related]
7. Determination of a clinically important difference and definition of a responder threshold for the UCSD performance-based skills assessment (UPSA) in patients with major depressive disorder.
Harvey PD; Jacobson W; Zhong W; Nomikos GG; Cronquist Christensen M; Kurre Olsen C; Merikle E
J Affect Disord; 2017 Apr; 213():105-111. PubMed ID: 28213121
[TBL] [Abstract][Full Text] [Related]
8. Using self-reported vocational functioning measures to identify employed patients with impaired functional capacity in major depressive disorder.
Murthy NV; Xu R; Zhong W; Harvey PD
J Affect Disord; 2020 Jan; 260():550-556. PubMed ID: 31539692
[TBL] [Abstract][Full Text] [Related]
9. A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD.
Mahableshwarkar AR; Jacobsen PL; Chen Y; Serenko M; Trivedi MH
Psychopharmacology (Berl); 2015 Jun; 232(12):2061-70. PubMed ID: 25575488
[TBL] [Abstract][Full Text] [Related]
10. The effects of vortioxetine on cognitive performance in working patients with major depressive disorder: A short-term, randomized, double-blind, exploratory study.
Baune BT; Sluth LB; Olsen CK
J Affect Disord; 2018 Mar; 229():421-428. PubMed ID: 29331703
[TBL] [Abstract][Full Text] [Related]
11. The effects of vortioxetine on cognitive dysfunction in patients with inadequate response to current antidepressants in major depressive disorder: A short-term, randomized, double-blind, exploratory study versus escitalopram.
Vieta E; Sluth LB; Olsen CK
J Affect Disord; 2018 Feb; 227():803-809. PubMed ID: 29673132
[TBL] [Abstract][Full Text] [Related]
12. Vortioxetine versus Duloxetine in the Treatment of Patients with Major Depressive Disorder: A Meta-Analysis of Randomized Controlled Trials.
Li G; Wang X; Ma D
Clin Drug Investig; 2016 Jul; 36(7):509-17. PubMed ID: 27067232
[TBL] [Abstract][Full Text] [Related]
13. A randomized, double-blind, placebo-controlled study of the efficacy and safety of 2 doses of vortioxetine in adults with major depressive disorder.
Mahableshwarkar AR; Jacobsen PL; Serenko M; Chen Y; Trivedi MH
J Clin Psychiatry; 2015 May; 76(5):583-91. PubMed ID: 26035186
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of vortioxetine versus agomelatine, categorized by previous treatment, in patients with major depressive disorder switched after an inadequate response.
Papakostas GI; Nielsen RZ; Dragheim M; Tonnoir B
J Psychiatr Res; 2018 Jun; 101():72-79. PubMed ID: 29554497
[TBL] [Abstract][Full Text] [Related]
15. The Effects of Vortioxetine on Cognitive Function in Patients with Major Depressive Disorder: A Meta-Analysis of Three Randomized Controlled Trials.
McIntyre RS; Harrison J; Loft H; Jacobson W; Olsen CK
Int J Neuropsychopharmacol; 2016 Jun; 19(10):. PubMed ID: 27312740
[TBL] [Abstract][Full Text] [Related]
16. Association between cognitive function and performance on effort based decision making in patients with major depressive disorder treated with Vortioxetine.
Subramaniapillai M; Mansur RB; Zuckerman H; Park C; Lee Y; Iacobucci M; Cao B; Ho R; Lin K; Phan L; McIntyre RS
Compr Psychiatry; 2019 Oct; 94():152113. PubMed ID: 31404802
[TBL] [Abstract][Full Text] [Related]
17. The efficacy profile of vilazodone, a novel antidepressant for the treatment of major depressive disorder.
Reed CR; Kajdasz DK; Whalen H; Athanasiou MC; Gallipoli S; Thase ME
Curr Med Res Opin; 2012 Jan; 28(1):27-39. PubMed ID: 22106941
[TBL] [Abstract][Full Text] [Related]
18. The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies.
Baldwin DS; Chrones L; Florea I; Nielsen R; Nomikos GG; Palo W; Reines E
J Psychopharmacol; 2016 Mar; 30(3):242-52. PubMed ID: 26864543
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Vortioxetine on Cognitive Functioning in Working Patients With Major Depressive Disorder.
McIntyre RS; Florea I; Tonnoir B; Loft H; Lam RW; Christensen MC
J Clin Psychiatry; 2017 Jan; 78(1):115-121. PubMed ID: 27780334
[TBL] [Abstract][Full Text] [Related]
20. A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder.
Mahableshwarkar AR; Jacobsen PL; Chen Y
Curr Med Res Opin; 2013 Mar; 29(3):217-26. PubMed ID: 23252878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
